Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer? Veröffentlicht vonadmin 27. Juli 2020 Huemer F, Gampenrieder SP, Schlattau A, Greil R. http://www.ncbi.nlm.nih.gov/pubmed/24246725